Immune System News and Research

RSS

Scientists reveals how cancer-causing p53 mutations remain invisible to the immune system

One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see.

17 Sep 2026

Innate immune system variations determine vaccine side effects

Redness and pain at the injection site, fever, fatigue or headaches: vaccines can cause side effects, but their frequency and severity vary considerably from person to person.

17 Sep 2026

Salk scientists demonstrate B cells directly enhance killer T cell function

Cancer is the second leading cause of death in the United States, according to a 2026 Cancer Research Institute report. Cancer biologists are keenly aware of this statistic, as it drives them to innovations that revolutionize cancer care-innovations like immunotherapy.

17 Sep 2026

AI tools help predict immunotherapy outcomes in lung cancer patients

Artificial intelligence (AI) tools can help physicians predict treatment and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy, according to a new study published in Nature Medicine.

16 Sep 2026

Norwegian scientists harvest super donor cells to fight diverse diseases

Cells from nine "super donors" are being collected in Oslo. The aim is for these to be used to repair or replace damaged cells, tissue and organs in people suffering from conditions ranging from heart attacks to Parkinson's disease.

16 Sep 2026

Study illuminates the link between the Epstein-Barr virus and multiple sclerosis

A new study illuminates the connection between the Epstein-Barr virus (EBV) and multiple sclerosis (MS), pointing to a causal role for reactivation of the virus in triggering MS attacks in people with certain genetic risk factors.

16 Sep 2026

Biological mechanisms validate structured exercise as therapeutic in oncology care

Structured exercise may help people with cancer live longer and have more time free of disease, finds a synthesis of the available evidence, published online in the British Journal of Sports Medicine.

16 Sep 2026

Natural anti-NMDAR1 antibody may protect the brain following traumatic brain injury

Every year, an estimated 20 million people worldwide sustain a concussion or other traumatic brain injury (TBI), which leads to a two- to four-fold increase in the risk of depression, anxiety and post-traumatic stress disorder (PTSD).

15 Sep 2026

Study uncovers how interferon-alpha treats rare blood cancers

The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators.

15 Sep 2026

Insilico Medicine launches AI initiative to develop longevity vaccines

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient's own immune cells to eliminate the earliest cellular drivers of age-related disease.

15 Sep 2026

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.

11 Sep 2026

Targeted nanoparticles strengthen anti-cancer immune responses in tumors

Adelaide University researchers have developed a new way of using mRNA technology to reprogram tumor-supporting immune cells and strengthen the body's anti-cancer immune response.

11 Sep 2026

Lupus-linked genetic variants may boost antiviral immunity

Why do genetic variants that increase the risk of autoimmune disease remain so common in the population?

11 Sep 2026

Study shows mRNA vaccines trigger more diverse flu antibody responses

Influenza remains a major global health challenge as continual antigenic drift can limit the breadth and durability of vaccine-induced antibody responses, requiring frequent vaccine updates.

11 Sep 2026

Early treatment significantly reduces joint damage in rheumatoid arthritis

Early and consistently managed treatment can have a decisive impact on the course of rheumatoid arthritis and prevent permanent joint damage.

11 Sep 2026

McMaster researchers discover molecular switch causing dangerous blood clots

A cross-campus team of McMaster University researchers has identified why some patients develop dangerous blood clots after exposure to a common blood thinner – and a potential way to prevent it.

11 Sep 2026

Chronic interferon exposure drives immunosuppression in tumors

Cancer biology and, in turn, cancer treatment have come a long way in the last few decades. Most people recognize this progress in breakthroughs like immunotherapy-a treatment strategy first deployed in 2011 that leverages the body's own immune cells to fight cancer and revolutionized the treatment landscape.

10 Sep 2026

Refined starch activates immune pathways after low-carb weight loss

After substantial weight loss on a very-low-carbohydrate diet, participants who switched to a diet rich in refined starch showed greater activation of circulating immune and metabolic pathways than those who continued the low-carbohydrate diet or consumed a high-carbohydrate diet rich in added sugar. Mouse experiments suggested that activation of the complement immune pathway may help explain the inflammatory response associated with starch intake.

10 Sep 2026

Rituximab alters T-cell metabolism in patients with nephrotic syndrome

Nephrotic syndrome is caused when the filtering system in the kidneys is damaged, allowing large amounts of protein to leak into the urine.

10 Sep 2026

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen. Additional proteomic analyses linked treatment to changes in senescence, metabolism, growth-factor signaling, and fibrosis-related pathways, although the study could not determine whether these effects reflected genuine geroprotection rather than disease modification.

10 Sep 2026